Amgen Inc. Stock Holds Defensive Ground Near 366 USD as Biotech Giant Targets 12% Annual Gain

NodeGuardian · 2026-03-16T07:46:19+00:00

Amgen Inc. demonstrates defensive stock qualities with a 12% gain in 2023, targeting $37.85 billion revenue by 2026. Analysts foresee growth, favorable risk-reward, strong cash flow, and a 3.19% dividend yield.

NodeGuardian

2026-03-16 07:46:19

Abstract generation in progress

Amgen Inc. (ISIN: US0311621009) is performing as a defensive stock, closing at $366.21 on March 13 with an almost 12% year-to-date gain, showcasing resilience in volatile markets. The biotech giant targets $37.85 billion in revenue for 2026, driven by strong performance in oncology, cardiovascular, and inflammatory disease segments. Analysts forecast continued growth and an attractive risk-reward profile for investors, supported by robust cash flow, a 3.19% dividend yield, and strategic deleveraging efforts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.